Psoriasis — So Yeon Paek, MD

Psoriasis Treatments

Click on each medication for more information.

Soluble TNF receptor IgG1 fusion protein (SQ)

Indications: psoriasis (PsO), pediatric PsO (age 4+), psoriatic arthritis (PsA), RA, AS

Human IL-17A mAB (SQ)

Indications: PsO, PsA, AS, axial spondyloarthritis

Human IL-23 subunit p19 blocker (SQ)

Indications: psoriasis, psoriatic arthritis

Pegylated humanized Fab’ of TNF-alpha (SQ)

Indications: PsO, PsA, Crohn’s, RA, AS, axial spondyloarthritis

Humanized IL-17A mAB (SQ)

Indications: PsO, pediatric PsO (age 6+), PsA, AS, axial spondyloarthritis

Humanized IL-23 subunit p19 blocker (SQ)

Indications: psoriasis

Human anti-TNF IgG1 mAB (SQ)

Indications: PsO, PsA, HS (age 12+), Crohn’s, UC, RA, AS, uveitis

Human monoclonal antibody that binds IL-17 receptor (SQ)

Indications: psoriasis

Humanized IL-23 subunit p19 blocker (SQ)

Indications: psoriasis

Chimeric IgG1 anti-TNF monoclonal antibody (IV infusion)

Indications: PsO, PsA, Crohn’s, UC, RA, AS

Human IL-12/23 mAB (SQ)

Indications: PsO, pediatric PsO (age 6+), PsA, Crohn’s, UC

PDE-4 inhibitor (ORAL)

Indications: psoriasis, psoriatic arthritis, Behcet’s disease

Human IL-4/13 Blocker

Indications: atopic dermatitis (age 6+), asthma, chronic rhinosinusitis